Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/2326-6066.CIR-15-0233 http://scihub22266oqcxt.onion/10.1158/2326-6066.CIR-15-0233 C5886853!5886853 !27401919     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27401919 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Immunol+Res 2016 ; 4 (9 ): 789-98 Nephropedia Template TP {{tp|p=27401919 |t=2016. Mutation Drivers of Immunological Responses to Cancer |pdf=|usr=}}{{27401919 }} gab.com Text Mutation Drivers of Immunological Responses to Cancer JO: Cancer Immunol Res http://www.kidney.de/pget.php?&tw=1&pmid=27401919 #FOAvip In cancer immunology, somatic missense mutations have been mostly studied with regard to their role in the generation of neoantigens. However, growing evidence suggests that mutations in certain genes, such as CASP8 or TP53, influence the immune response against a tumor by other mechanisms. Identifying these genes and mechanisms is important because, just as the identification of cancer driver genes led to the development of personalized cancer therapies, a comprehensive catalog of such cancer immunity drivers will aid in the development of therapies aimed at restoring antitumor immunity. Here, we present an algorithm, domainXplorer, that can be used to identify potential cancer immunity drivers. To demonstrate its potential, we used it to analyze a dataset of 5,164 tumor samples from The Cancer Genome Atlas (TCGA) and to identify protein domains in which mutation status correlates with the presence of immune cells in cancer tissue (immune infiltrate). We identified 122 such protein regions, including several that belong to proteins with known roles in immune response, such as C2, CD163L1, or FC?R2A. In several cases, we show that mutations within the same protein can be associated with more or less immune cell infiltration, depending on the specific domain mutated. These results expand the catalog of potential cancer immunity drivers and highlight the importance of taking into account the structural context of somatic mutations when analyzing their potential association with immune phenotypes. Cancer Immunol Res; 4(9); 789-98. ©2016 AACR. Twit Text FOAVip Mutation Drivers of Immunological Responses to Cancer ????Cancer Immunol Res http://www.kidney.de/pget.php?&tw=1&pmid=27401919 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27401919 #FOAvip English Wikipedia <ref>{{Cite pmid|27401919 }}</ref> Mutation Drivers of Immunological Responses to Cancer #MMPMID27401919 Porta-Pardo E ; Godzik A Cancer Immunol Res 2016[Sep]; 4 (9 ): 789-98 PMID27401919 show ga In cancer immunology, somatic missense mutations have been mostly studied with regard to their role in the generation of neoantigens. However, growing evidence suggests that mutations in certain genes, such as CASP8 or TP53, influence the immune response against a tumor by other mechanisms. Identifying these genes and mechanisms is important because, just as the identification of cancer driver genes led to the development of personalized cancer therapies, a comprehensive catalog of such cancer immunity drivers will aid in the development of therapies aimed at restoring antitumor immunity. Here, we present an algorithm, domainXplorer, that can be used to identify potential cancer immunity drivers. To demonstrate its potential, we used it to analyze a dataset of 5,164 tumor samples from The Cancer Genome Atlas (TCGA) and to identify protein domains in which mutation status correlates with the presence of immune cells in cancer tissue (immune infiltrate). We identified 122 such protein regions, including several that belong to proteins with known roles in immune response, such as C2, CD163L1, or FC?R2A. In several cases, we show that mutations within the same protein can be associated with more or less immune cell infiltration, depending on the specific domain mutated. These results expand the catalog of potential cancer immunity drivers and highlight the importance of taking into account the structural context of somatic mutations when analyzing their potential association with immune phenotypes. Cancer Immunol Res; 4(9); 789-98. ©2016 AACR. |*Mutation [MESH] |Antigens, Neoplasm/immunology [MESH] |Biomarkers [MESH] |Cadherins/chemistry/metabolism [MESH] |Complement System Proteins/chemistry/genetics/immunology [MESH] |Computational Biology/methods [MESH] |Gene Expression Profiling [MESH] |Humans [MESH] |Immunomodulation/*genetics [MESH] |Models, Molecular [MESH] |Neoplasms/*genetics/*immunology/metabolism [MESH] |Phenotype [MESH] |Protein Binding [MESH] |Proteomics [MESH] |Structure-Activity Relationship [MESH]Mutation Drivers of Immunological Responses to Cancer (epmc).pdf DeepDyve Pubget Overpricing